GRADE
[대역어] 등급
[용어속성] Term
[용어속성] Term
Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial
비경구 3가 P2-VP8 소단위 로타바이러스 백신의 안전성 및 면역원성: 다중 부위, 무작위, 이중 맹검, 위약 대조 시험
Article
[키워드] adjusted
Adults
adverse event
adverse events
African
age
All participants
analysed
Antigen
assigned
baseline
block
block size
block sizes
blocks
blood sample
Blood samples
Comparisons
death
Deltoid muscle
dose
dose-escalation
double-blind
Efficacy
elicited
eligible
enrolment
evaluate
febrile
febrile convulsion
Final
finding
FIVE
foundation
funding
geometric mean
geometric mean titre
gestation
GRADE
group
groups
HIV infection
IgA
IgG
IgG seroresponse
IgG seroresponses
immunogenic
immunogenicity
immunogenicity endpoint
Infant
Infants
injection
Injections
Intramuscular injection
Laboratory
Local
Melinda Gate
Melinda Gates
Meningitis
multisite
neutralising antibody
neutralising antibody response
Neutralising antibody responses
neutralising antibody seroresponse
neutralising antibody seroresponses
no significant difference
no significant differences
occurred
parent
parents
participant
Participants
Placebo
placebo group
placebo recipient
placebo recipients
placebo-controlled
placebo-controlled trial
pneumococcal
pneumococcal meningitis
protocol
randomisation
randomised
Randomly
receive
recipient
Registered
Research
respiratory
Respiratory tract infections
response
responses against
rotavirus vaccination
rotavirus vaccine
Safety
safety endpoint
Serious Adverse Event
Serious Adverse Events
serum
significantly higher
South
South Africa
Strains
subunit
Support
systemic adverse events
systemic reaction
systemic reactions
the placebo group
the vaccine
timepoints
Treatment
Trial
trivalent
USA
Vaccine
was done
were assessed
[DOI] 10.1016/S1473-3099(20)30001-3 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/S1473-3099(20)30001-3 PMC 바로가기 [Article Type] Article
Contingency Nursing Management in Designated Hospitals During COVID-19 Outbreak
Article and Review
[키워드] administration
adopted
Care
China
class
contingency
COVID-19
COVID-19 pandemic
COVID-19 patient
COVID-19 patients
cured
discharged
effective
GRADE
Guangdong
health emergency
healthcare
hospital
Hospitalized
implementation phase
management
measure
Measures
National
non-COVID-19 patient
Nurse
Nursing
positive
provided
Research
resource
responsible
spread of COVID-19
Support
Treatment
virus
Wuhan, China
[DOI] 10.5334/aogh.2918 PMC 바로가기 [Article Type] Article and Review
[DOI] 10.5334/aogh.2918 PMC 바로가기 [Article Type] Article and Review
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial
AGILE-ACCORD: COVID-19 치료를 위한 여러 후보 약제의 최적 용량, 안전성 및 효능을 결정하기 위한 무작위, 다기관, 원활한, 적응 I/II상 플랫폼 연구: 무작위 플랫폼에 대한 연구 프로토콜의 구조화된 요약 재판
Letter
[키워드] 9-point ordinal scale
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
adaptive
added
Adult patients
Adverse
adverse events
agent
Anti-viral treatment
approval
Bayesian
Blinding
candidate
Candidates
clinical
Clinical improvement
cloud
Cohort
cohorts
Combination
Common Terminology Criteria
Community
community setting
comparator
contributing to
coronavirus
COVID-19
COVID-19 infection
CST
cytokine
cytokine release
death
defined
determine
disease
dissemination
dose
EDC
Efficacy
Efficacy and safety
element
eligibility criteria
eligible
England
EudraCT
evaluated
expected
for inclusion
futility
GRADE
group
hospitalised
hospitalised patient
Hospitalization
in some
include
Infection
intubation
Ireland
laboratory-confirmed
later phase
limit
Mask
Master protocol
mechanical ventilation
mechanism
mechanism of action
multi-arm
multicentre
Multiple
nasal prongs
non-invasive ventilation
North
number
objective
open
Open-label
opens
optimal dose
Ordinal Scale
organ
Other
outcome
oxygen
oxygen saturation
oxygen)
participant
Patient
patient population
patients
peripheral capillary
Peripheral capillary oxygen saturation
phase
Phase I/II
Placebo
platform
Platform study
Platform trial
Population
Prevent
progression of disease
promise
protocol
randomisation
randomised
Rave
recruited
recruitment
Regulatory
required
respiratory
Safety
Sample size
SARS-CoV-2
SARS-COV-2 infection
seamless
setup
severe acute respiratory syndrome Coronavirus
severe disease
shown
SOC
Specific
Stage
Standard
Standard of care
status
Study protocol
the WHO
toxicities
Toxicity
Treatment
treatment of COVID-19
Trial
Trial registration
Ventilation
Viral
Viral load
viral replication
website
WHO
working
[DOI] 10.1186/s13063-020-04473-1 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04473-1 PMC 바로가기 [Article Type] Letter
Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II)
중증 COVID-19 환자를 치료하기 위한 동종 인간 치수 줄기세포의 안전성 및 효능 평가: 무작위 대조 시험(I/II상)을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
Acidic
Adenovirus
Admission
AIDS
Alanine
alanine aminotransferase
albumin
alkaline phosphatase
Allogeneic
allogeneic human dental pulp stem cells
amyloid
Analysis
anion gap
Arm ratio
aspartate
Aspartate aminotransferase
average
B lymphocyte
basophils
Before menopause
Bilirubin
blind
blinded
Block randomization method
Blood
blood cell
Blood cells
blood pressure
Blood routine
C-reactive protein
calcium
carbon dioxide
Care
CAST
caused
Cell
cell suspension
change
chest X-ray
Child Pugh score
chlorine
cholesterol
cholinesterase
CLARITY
clinical
Clinical improvement
clinical trial
coded
Coefficient of variation
color
commenced
comparator
computer
Concentration
Consent
consent form
Continuous renal replacement therapy
control group
control groups
COVID-19
COVID-19; randomised controlled trial; protocol; human dental pulp stem cells; dental stem cell banking
COVID-2019
creatine
creatine kinase
creatinine
criteria
crystal
Cytokines
cytomegalovirus
cytomegalovirus CMV-IgG
cytomegalovirus CMV-IgM
Definition
dental pulp
dental pulp stem cells
description
detect
Diastolic blood pressure
direct bilirubin
discharge
disease
dissemination
distress
distribution
DPSCs
ECMO
Efficacy
element
enrolled
eosinophil
eosinophils
epithelial cells
estimated glomerular filtration rate
Estrogen
examined
excluded
exclusion criteria
experimental group
fat globules
Female patients
female subject
filtration rate
Final
flow cytometry
follow-up period
fungi
fungus
Globulin
glomerular filtration rate
Glucose
GRADE
Grade 1
grade 3
Grade 5
granulocyte
HBcAb
HBeAb
HBeAg
HBsAb
HBsAg
hDPSCs
Health Organization
heart rate
hematocrit
Hemodialysis
hemoglobin
hepatitis B
hepatitis C
HFNC
high density lipoprotein
hospitalised patient
Hospitalised patients
Hospitalization
Hospitalized
human DPSC
human DPSCs
hypersensitive C-reactive protein
hypoxia
Identifier
IgA
IgG
IgM
Il -10
IL-1
IL-1 β
IL-2
IL-4
IL-6
immune
Immunoglobulin
Immunological testing
improvement
IMV
inclusion criteria
Infectious disease
Influenza
Influenza virus
informed consent form
injection
Injections
intensive care
intensive care unit
Intravenous injection
Invasive mechanical ventilation
investigator
investigators
ITN-γ
ketone
ketone bodies
Kidney function
Kidney function tests
Killer cell
Laboratory
laboratory examinations
Lactate
lactate dehydrogenase
lactating women
leukocyte
leukocyte enzymes
lipoprotein
lipoprotein A
lipoprotein cholesterol
low density lipoprotein
lung lesion
lung lesions
lymphocyte
Lymphocytes
Macrophage
Magnesium
Medical care
Menopause
Monocytes
mononuclear cell
mononuclear cells
nasal
nasal catheter
natural killer
natural killer cell
neutrophil
Neutrophils
nitrite
NIV
Non-invasive
non-invasive mechanical ventilation
non-squamous epithelial cell
non-squamous epithelial cells
nucleic acid
nucleic acid test
number
objective
observation
occult
occult blood
Other
Other condition
outcome
oxygen
oxygen saturation
parallel group
parasites
partial pressure
participant
Patient
penetration
performed
Peripheral blood
Peritoneal dialysis
phase
phenotype
phosphatase
phosphorus
Placebo
placebo-controlled
Platelet
Platelet count
platelet distribution width
Platelets
Potassium
prealbumin
pregnancy test
pregnant
pressure
Primary outcome
Protein
protocol
random
randomisation
randomization
Randomized
Randomized controlled trial
receive
receiving
recruitment
red blood cell
red blood cells
renal
renal insufficiency
renal replacement therapy
Renmin Hospital
replacement therapy
required
researcher
respiratory
respiratory distress
respiratory infection
respiratory rate
Safety
Saline
saline solution
Sample size
SARS-CoV-2
secondary
Secondary outcomes
serious COVID-19
serum
serum amyloid
severe liver condition
severe pneumonia
single-cell analyses
sodium
specific gravity
Standard deviation
status
stem cell
study period
Study protocol
sugar
syphilis
Systolic blood pressure
T lymphocyte
Th1 cytokine
Th1 cytokines
Th2 cytokine
Th2 cytokines
therapeutic effect
therapeutic effects
time
TNF-a
Total
total bilirubin
Total cholesterol
total protein
traits
Transferrin
treat
Treatment
treatment for COVID-19
triacylglycerol
Trial
triple blinded
TTCI
Tuberculosis
Twenty participant
Twenty participants
university
urea
uric acid
Urine
urobilinogen
Variation
Version
vital signs
Volume
website
White blood cells
with HIV
within 6 months
women
World Health Organization
Wuhan
γ-glutamyl transferase
[DOI] 10.1186/s13063-020-04380-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04380-5 PMC 바로가기 [Article Type] Letter
Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China
Review
[키워드] assigned
China
clinical evidence
coronavirus disease
COVID-19
COVID-19 epidemic
COVID-19 patients
COVID-2019
Critical care
Critically ill
Critically ill patient
develop
Diagnosis
draft
dynamic
epidemiological
etiological
Expert statement
functional
GRADE
Grade 1
Immunity
impairment
intensive care
management
organ
organ function
organized
pandemic
Part
participant
Patient
Psychological interventions
recommendation
recommendations
resource
Result
Support
Supportive treatment
targeted therapy
therapy
tissue
Treatment
was obtained
with COVID-19
Wuhan
Wuhan, China
[DOI] 10.1186/s13613-020-00689-1 PMC 바로가기 [Article Type] Review
[DOI] 10.1186/s13613-020-00689-1 PMC 바로가기 [Article Type] Review
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
95% CI
absence
addition
administration of hydroxychloroquine
Admission
aerosol-generating procedures
allergy
analyzed
Anesthesia
antibody
approved
ARMS
assigned
balanced randomization
blind
Cancer
Cantabria
carried
CDC
Cell
Chemoprophylaxis
clinical
Clinical data
clinically
coated
Committee
comparator
Comparator group
computer-generated
control group
Controlled
Controlled clinical trial
Controlled trial
coronavirus
COVID
COVID-19
criteria
CURB
current
detect
Determination
disease
dissemination
double blind
double-blind
dropout rate
Efficacy
Efficacy and safety
element
ELISA kit
Emergency
Endocrine
estimate
Ethics
Euroimmun
Evidence
evidence of
Germany
GRADE
greater
group
Health
Health authority
health-care
healthcare personnel
Healthcare professional
healthcare professionals
heart
heart failure
help
hematological
high risk
hospital
Hydroxychloroquine
hydroxychloroquine sulfate
hygiene
Hypothesis
ICU
IDT
IgA
IgG
IgM and IgG
immune
immunodeficiency
in vitro
incidence
include
Infection
inhibit
intensive care unit
Intervention
investigator
kidney
lactation
liver
measure
Measures
Medicine
Negative PCR
neurological
New York
number
observation period
outcome
participant
PCR
performed
Personal protective equipment
Placebo
positive
positive SARS-CoV-2 PCR
positive serology
Pregnancy
presenting
Prevalence
Primary outcome
probes
product
professional
Prophylaxis
Prospective
PROTECT
Protective
protocol
Psychiatric
randomised
randomised controlled trial
randomization
Randomized
randomized trial
RCT
receive
recruitment
reduce
reported
responsible
risk
RT-PCR
Sample size
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 PCR
sequence
Seroconversion
serological
serology
severity
Significant
single center
single-center study
social distancing
Spain
Spanish
Standard
Statistical power
status
Study protocol
subject
Support
Symptom
symptomatic and asymptomatic
Tablet
Takara
Taking
Tamoxifen
Transmission
Treatment
two-tailed
university
Vaccine
virus
website
while
[DOI] 10.1186/s13063-020-04400-4 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04400-4 PMC 바로가기 [Article Type] Letter
Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology
Special Article
[키워드] anticoagulation
Bacterial
Betacoronavirus
Brasil
Brazil
Chloroquine
clinical trials
conducted
Coronavirus infections/drug therapy
Corticosteroids
COVID-19
Diretrizes
effective
Effectiveness
Evidence
GRADE
guideline
guidelines
hospitalized patients
Infecções por coronavirus/tratamento farmacológico
Infectious disease
Influenza
information
Interpretation
Intervention
Medicine
methodologist
oseltamivir
Patient
pharmacological
pharmacological treatment
professional
provided
Pulmonology
Rapid
recommendation
Result
Safe
SARS-CoV-2
Society
systematic reviews
Therapies
therapy
Tocilizumab
treated
Treatment
use of hydroxychloroquine
was performed
[DOI] 10.5935/0103-507X.20200039 PMC 바로가기 [Article Type] Special Article
[DOI] 10.5935/0103-507X.20200039 PMC 바로가기 [Article Type] Special Article
Is acyclovir effective for the treatment of varicella in children and adolescents?
Review
[키워드] Acyclovir.
Epistemonikos
GRADE
varicella
[DOI] 10.5867/medwave.2018.06.7268 [Article Type] Review
[DOI] 10.5867/medwave.2018.06.7268 [Article Type] Review
Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial
항레트로바이러스 요법(REALITY)을 시작하는 아프리카의 심각한 면역 저하 HIV 감염 개인의 사망률에 대한 즉시 사용 가능한 보충 식품의 효과: 공개, 병렬 그룹, 무작위 대조 시험
Article
[키워드] 1:1
95% CI
adverse event
adverse events
age
analysed
anti-infection
Antiretroviral therapy
ART
assigned
block size
BMI
body-mass
body-mass index
both groups
CD4 cell
Cell
changes in
children
clinic visit
Clinic visits
computer-generated
database
Department
development
died
Dispensing
Effect
eight
Eligible participants
Evidence
evidence of
finding
funding
global health
GRADE
greater
hazard ratio
high risk
HIV infection
hospital
hypothesise
Immunocompromised
in both group
individual
individuals
infected individuals
infections
Intention
intention to treat
Interaction
ISRCTN
ISRCTN registry
Kenya
log-rank
Medical Research Council
medication
micronutrients
Mortality
no evidence of
nutritional status
Older
Open-label
outcome
parallel-group
participant
Participants
peanut
per day
Policy
present
Primary outcome
Prophylaxis
raltegravir
randomisation
randomised controlled trial
Randomly
ready-to-use therapeutic food
reducing
Registered
reported
Safety
secondary
Secondary outcomes
Serious Adverse Event
Serious Adverse Events
significantly
stratified
sub-Saharan Africa
Symptom
Trial
Uganda
vital status
weight
weight gain
Wellcome Trust
would increase
Z score
Zimbabwe
[DOI] 10.1016/S2352-3018(18)30038-9 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/S2352-3018(18)30038-9 PMC 바로가기 [Article Type] Article